HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Zhejiang Orient Gene Biotech C / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/zhejiang-orient-gene-biotech-a" target="_blank" data-smartkarma-citation="entities:30379:1" rel="noopener">Zhejiang Orient Gene Biotech-A (688298 CH) </a>(Orient Biotech) is a company specializing in the R&amp;D, production and sales of IVD products, with main business in the field of POCT (point-of-care testing). According to its financial reports, Orient Biotech achieved high growth in both 2020 and 2021Q1. In 2020, the revenue was RMB3.265 billion, up 788.83% YoY. Net profit attributed to shareholders was RMB1.677 billion, up 1,942.94% YoY. In 2021Q1, the Company achieved revenue of RMB2.236 billion, up 1925.91% YoY. Net profit attributed to shareholders was RMB1.186 billion, up 2601.42% YoY. This insight mainly analyzed the industry characteristics, the business, the valuation and the key risks of Orient Biotech.

Zhejiang Orient Gene Biotech-A (688298 CH) (Orient Biotech) is a company specializing in the R&amp;D, production and sales of IVD products, with main business in the field of POCT (point-of-care testing). According to its financial reports, Orient Biotech achieved high growth in both 2020 and 2021Q1. In 2020, the revenue was RMB3.265 billion, up 788.83% YoY. Net profit attributed to shareholders was RMB1.677 billion, up 1,942.94% YoY. In 2021Q1, the Company achieved revenue of RMB2.236 billion, up 1925.91% YoY. Net profit attributed to shareholders was RMB1.186 billion, up 2601.42% YoY. This insight mainly analyzed the industry characteristics, the business, the valuation and the key risks of Orient Biotech.

Zhejiang Orient Gene Biotech (688298.CH) - Clearly Undervalued with Attractive Upside Potential

Shenzhen Lifotronic Technology-A / Equity Bottom-Up

Since this year, major shareholders of <a href="https://www.smartkarma.com/entities/shenzhen-lifotronic-techno-a" target="_blank" data-smartkarma-citation="entities:30395:1" rel="noopener">Shenzhen Lifotronic Techno-A (688389 CH)</a> have reduced their holdings by 4.22 million shares, which still hasn't affected the performance of its stock price. Lifotronic’s share price was up about 34.6% by the end of June 11, 2021, thanks to the Company's strong growth. From 2016 to 2020, Lifotronic's revenue increased from RMB175 million to RMB554 million, with a CAGR of 33.47%. The net profit increased from RMB33.4 million (excluding the share-based payment of RMB23.5 million) in 2016 to RMB144 million in 2020, with a CAGR of 44.12%. The operating cash flow increased from RMB28 million in 2016 to RMB136 million in 2020, with a CAGR of 48.57%. Considering Lifotronic’s solid performance for years, this company deserves investors’ following.

Since this year, major shareholders of Shenzhen Lifotronic Techno-A (688389 CH) have reduced their holdings by 4.22 million shares, which still hasn't affected the performance of its stock price. Lifotronic’s share price was up about 34.6% by the end of June 11, 2021, thanks to the Company's strong growth. From 2016 to 2020, Lifotronic's revenue increased from RMB175 million to RMB554 million, with a CAGR of 33.47%. The net profit increased from RMB33.4 million (excluding the share-based payment of RMB23.5 million) in 2016 to RMB144 million in 2020, with a CAGR of 44.12%. The operating cash flow increased from RMB28 million in 2016 to RMB136 million in 2020, with a CAGR of 48.57%. Considering Lifotronic’s solid performance for years, this company deserves investors’ following.

Shenzhen Lifotronic Technology (688389.CH)-A Dark Horse in Both IVD and Therapeutical Medical Device

Thematic (Sector/Industry)

Compared with traditional diagnostic products, the value and competitive advantage of POCT (point-of-care testing) diagnostic products are more obvious: for example, small instruments, easy to operate, no pollution, easy maintenance, and faster detection speed. The following mainly analyzed the POCT market and related investment opportunities in China.

Compared with traditional diagnostic products, the value and competitive advantage of POCT (point-of-care testing) diagnostic products are more obvious: for example, small instruments, easy to operate, no pollution, easy maintenance, and faster detection speed. The following mainly analyzed the POCT market and related investment opportunities in China. 

Industry Report: Insights on China IVD Industry - The POCT Market

Compared with developed countries, China's IVD industry started relatively late, and the overall technical level still lags far behind that of developed countries in Europe and America. However, in recent years, with the acceleration of the aging problem and the continuous growth of residents' income, the IVD has become one of the most active and fastest growing industries in China.

Compared with developed countries, China's IVD industry started relatively late, and the overall technical level still lags far behind that of developed countries in Europe and America. However, in recent years, with the acceleration of the aging problem and the continuous growth of residents' income, the IVD has become one of the most active and fastest growing industries in China. 

Industry Report - Insights on China IVD Industry

1. Industry viewpoints:
<ul>
<li>As the population ages, it is expected that the domestic dental prosthesis market has a great potential for development.</li>
<li>In the future, the market of China medical beauty has a broad space for growth.</li>
<li>POCT (point-of-care testing) has gained popularity in recent years and has become one of the fastest growing IVD tracks.</li>
</ul>
2. Company news:
News from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a> , <a href="https://www.smartkarma.com/entities/shanghai-fosun-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:8045:1" rel="noopener">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>, Aravive and <a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology Company Limited (1833 HK)</a> about the progress of new drugs, vaccine for COVID-19, new license agreement and the establishment of the Internet Eye Center.
3. Market review:
Last week, stock price for healthcare sector in A share decreased 1.23%, while CSI 300 decreased 0.59% over the same period of time. 
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:

As the population ages, it is expected that the domestic dental prosthesis market has a great potential for development.
In the future, the market of China medical beauty has a broad space for growth.
POCT (point-of-care testing) has gained popularity in recent years and has become one of the fastest growing IVD tracks.

2. Company news:
News from BeiGene Ltd (6160 HK) , Shanghai Fosun Pharmaceutical (Group) (2196 HK), Aravive and Ping An Healthcare and Technology Company Limited (1833 HK) about the progress of new drugs, vaccine for COVID-19, new license agreement and the establishment of the Internet Eye Center.
3. Market review:
Last week, stock price for healthcare sector in A share decreased 1.23%, while CSI 300 decreased 0.59% over the same period of time. 
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China

Guangzhou Wondfo Biotech Co.,Ltd. was founded in 1992. The company's line of business includes manufacturing of medical diagnostic tests.  Guangzhou Wondfo Biotech serves customers around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Guangzhou Wondfo Biotech C-A (300482 CH)

Zhejiang Orient Gene Biotech (688298.CH) - Clearly Undervalued with Attractive Upside Potential

This article mainly analyzed Zhejiang Orient Gene Biotech in terms of the industry characteristics, the business, the comparison with peers, the...

Xinyao (Criss) Wang

Shenzhen Lifotronic Technology (688389.CH)-A Dark Horse in Both IVD and Therapeutical Medical Device

This article analyzed "a dark horse" in IVD and therapeutical medical device, Lifotronic, including business analysis, drivers for revenue,...

Xinyao (Criss) Wang

Industry Report: Insights on China IVD Industry - The POCT Market

The article analyzed China POCT market in terms of market potential, market segmentations (infectious diseases, cardiac biomarkers,diabetes,blood...

Xinyao (Criss) Wang

Industry Report - Insights on China IVD Industry

The article analyzed China IVD industry in terms of business mode, trend on efficiency and size of equipment and operation, opportunity in import...

Xinyao (Criss) Wang

China Healthcare Weekly (Nov.13)

The article summarized the major industry viewpoints, company news and capital market review for China healthcare industry in the week of November...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)